Southeast Asia is home to a growing population of >600 million people, the majority younger than 65 years, but among whom, rapid epidemiological transition has led to high rates of premature death from non-communicable diseases (chiefly cardiovascular disease) (up to 28% in the Philippines vs. 12% in UK). There is a strikingly high prevalence of stage A heart failure (HF) risk factors in Southeast Asia, particularly hypertension (>24% in Cambodia and Laos vs. 13-15% in UK and USA), tobacco smoking (>36% in Indonesia), physical inactivity (>50% in Malaysia) and raised blood glucose (10-11% in Brunei, Malaysia, Singapore and Thailand) in spite of a low prevalence of overweight/obesity (21-26% in Southeast Asia vs. 67-70% in UK and USA). Accordingly, the prevalence of symptomatic HF appears to be higher in Southeast Asian countries compared with the rest of the world. Epidemiologic trends in Singapore showed a sharp 38% increase in age-adjusted HF hospitalizations (from 85.4 per 10 000 in 1991 to 110.3 per 10 000 in 1998) with notable ethnic differences (hospitalization rates~35% higher in Malays and Indians vs. Chinese; mortality 3.5 times higher in Malays vs. Indians and Chinese). Furthermore, Southeast Asian patients present with acute HF at a younger age (54 years) compared with USA patients (75 years) but have more severe clinical features, higher rates of mechanical ventilation, longer lengths of stay (6 vs. 4.2 days) and higher in-hospital mortality (4.8 vs. 3.0%). Finally, there is under-usage of guideline-recommended HF medical therapies (prescribed in 31-63% of patients upon discharge) and device therapies in Southeast Asia. Large gaps in knowledge that need to be addressed in Southeast Asia include the prevalence of HF with preserved ejection fraction, clinical outcomes, barriers to recommended therapies and their cost-effectiveness, as well as possible ethnicity-specific pathophysiologic mechanisms.
Southeast Asia refers to the geographic sub-region of Asia south of China, east of India, west of New Guinea and north of Australia and includes the states of the Association of Southeast Asian Nations (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam) ( Table 1 ). The region is notable for its unique history and sociocultural heterogeneity and is home to a rapidly growing population of >600 million people, the majority of whom are younger than 65 years. Recent globalisation and development have led to a rapid epidemiological transition in the region, as evidenced by a reduction in deaths from communicable diseases, an increase in average life expectancy, and an epidemic rise in non-communicable diseases, chief among which is cardiovascular disease. In fact, according to the World Health Organization 2014 global status report, the probability of premature death from non-communicable diseases far exceeds that of the UK (12.0%) in many countries in Southeast Asia, with more than double the risk in the Philippines (27.9%), Myanmar (24.3%) and Laos (24.2%). The risk of premature death from non-communicable diseases is also high in Indonesia (23.1%), Malaysia (19.6%), Cambodia (17.7%), Vietnam (17.4%), Brunei (16.8%) and Thailand (16.2%); with Singapore (10.2%) being the only exception with comparable risk with the UK.
Risk factors for heart failure in Southeast Asia
The cardiovascular risk factors in Table 1 represent the population with Stage A HF; according to current international HF guidelines. 1 In this context, striking features of Southeast Asian patients at risk of progression to symptomatic HF are observed. Firstly, the prevalence of hypertension in Southeast Asians is high (>24% in Cambodia and Laos) compared with the UK (15.2%) or USA (13.4%). Secondly, in spite of a much lower prevalence of overweight/obesity (21.6-26.2% in Southeast Asia vs. 66.7% in UK and 69.6% in USA), raised blood glucose/diabetes is a notable risk factor among Southeast Asians, reaching similarly high prevalence in Brunei, Malaysia, Singapore and Thailand compared with the UK and USA. Finally, the high prevalence of smoking is of concern, with smoking rates much higher in Southeast Asian countries (up to 36.5% in Indonesia) than UK or USA, except in Brunei and Singapore. This adverse lifestyle habit, coupled with physical inactivity particularly in Malaysia (51.6%), may contribute to the high premature mortality from cardiovascular diseases in these Southeast Asian countries.
These data have important implications for (1) a high population attributable risk of hypertension for the development of HF in Southeast Asia; (2) a strong cardiometabolic basis for HF in a unique 'lean diabetic' Southeast Asian phenotype, distinct from HF in Western patients where diabetes is closely linked to obesity; (3) public health preventive strategies that are urgently needed to reduce smoking and promote physical activity in Southeast Asia.
Epidemiology of clinical heart failure in Southeast Asia
In sharp contrast to the wealth of epidemiologic data on HF in Western populations, reliable population-based data on the incidence, prevalence and secular trends of clinical (Stage C) HF are scarce in Southeast Asia. Limited single-centre data in Malaysia and Singapore suggest that the prevalence of HF in Southeast Asian countries is higher compared with countries in the rest of the world (4.5-6.7% vs. 0.5-2% respectively) ( Figure 1) . 2 In an epidemiologic survey of HF hospitalizations among the elderly (≥65 years old) in Singapore from 1991-1998 (n=15 774; 77% Chinese, 14% Malay and 10% Indians), 3 a 38% increase in age-adjusted HF hospitalization rates was clearly demonstrated (from 85.4 per 10 000 in 1991 to 110.3 per 10 000 in 1998), whereas mortality decreased by 20% (from 7.3 per 10 000 in 1991 to 6.1 per 10 000 in 1998). Interestingly, significant ethnic differences were observed, wherein HF hospitalization rates were~35% higher in Malays and Indians compared with Chinese; and mortality was 3.5 times higher in Malays compared with both Indians and Chinese, with mortality rates climbing over 1991-1998 only among the Malays (but declining in Indians and Chinese). More contemporary (2002) (2003) (2004) ) data from two centres in Singapore (n=668; 72% Chinese, 17% Malay and 11% Indian) 4 confirmed higher HF readmission rates in Indians and Malays, as well as higher mortality rates in Malays. Whereas greater prevalence of diabetes and atherosclerotic vascular disease explained the higher event rates among Indians, the reasons for poorer prognosis among Malays remained unclear.
Unique characteristics of Southeast Asian patients with symptomatic heart failure
To date, the best available published data allowing comparisons of Asian to Western patients hospitalized with acute HF are from the Acute Decompensated Heart Failure Registry (ADHERE) International-Asia Pacific study that included the Southeast Asian countries of Indonesia, Philippines, Singapore and Thailand. 5 In the overall cohort, Asian Pacific patients were younger (median age 67 years vs. 75 years), but yet had more severe clinical features and higher rates of mechanical ventilation, compared with patients in the parallel US-based ADHERE registry. 6 Specifically among Southeast Asian patients in the ADHERE-Asia Pacific study, the mean age at presentation was even younger (54 years). 7 Despite the younger age of patients, length of stay was longer (6 vs. 4.2 days), and in-hospital mortality higher (4.8 vs. 3.0%), in ADHERE Asia-Pacific compared with ADHERE US. 6 
Medical therapy of heart failure in Southeast Asia
Under-usage of disease-modifying HF therapies was reported in the ADHERE Asia-Pacific cohort, with angiotensin-convertingenzyme inhibitors or angiotensin receptor blockers prescribed upon discharge in 63%, beta-blockers in 41% and mineralocorticoid receptor antagonists in 31% of patients. The frequency of use of these HF therapies appeared to be even lower among the Southeast Asian subset of patients. 7 Key gaps in knowledge include reasons for under-treatment of patients as well as the tolerability and effective HF drug doses in Southeast Asian patients, in whom smaller body sizes may impact the maximum tolerated doses or prescription habits of doctors.
Heart failure with preserved ejection fraction in Southeast Asia
The high prevalence of hypertension and rapidly ageing societies in Southeast Asia portend a large increase in heart failure with preserved ejection fraction (HFpEF). Currently, very little is known regarding the prevalence and outcome of patients with HFpEF from Southeast Asia. Retrospective single-centre studies have reported prevalences of HFpEF ranging from 17-38%. 4, 9, 10 Most recently, the 2-year mortality in 751 patients with HFpEF from Singapore was found to be 26.6% (compared with 37.1% in patients with reduced ejection fraction [HR 0.618; 95% CI 0.508-0.753]), with no ethnic differences. 10 Advanced heart failure therapies in Southeast Asia
Data are scarce regarding the use of advanced HF therapies, such as device therapy (implantable cardiac defibrillators, 11 and conflicting efficacy data in Asian patients. 12, 13 Important gaps in knowledge include real world rates of key clinical events (such as sudden cardiac death) in Southeast Asian HF patients, costeffectiveness of device therapy within the varied healthcare systems of Southeast Asia and sociocultural barriers to device therapy. These issues are being assessed prospectively in the ongoing Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) Registry [ClinicalTrials.gov Identifier: NCT01633398]. 14 
Conclusions
The facts and figures show that HF is a bourgeoning problem in Southeast Asia, fueled by a rapidly growing population with Stage A HF risk factors particularly hypertension, diabetes, in spite of relative lack of obesity, and smoking. Limited data in symptomatic Stage C HF patients from Southeast Asia indicate that HF hospitalizations are on the rise, and that compared with Western counterparts, HF decompensation occurs at a younger age and yet is characterized by more severe clinical features and worse outcomes in Southeast Asian patients. Important inter-ethnic differences exist, wherein Malay patients appear to fare worse than Indian or Chinese patients, for reasons that are poorly understood. Underusage of disease-modifying HF therapies has been reported among Southeast Asian patients. There are large gaps in knowledge pertaining to the prevalence of HFpEF, clinical outcomes, barriers to recommended therapies and their cost-effectiveness in Southeast Asia, as well as possible ethnicity specific pathophysiologic mechanisms. These gaps will hopefully be addressed in ongoing studies (SHOP, 8 PEOPLE, 8 
ASIAN-HF 14
).
